These data demonstrate that reducing PDGF expression using RNAi inhibits the expression of glial fibrillary acidic protein (GFAP), substance p (SP), calcitonin gene-related peptide (CGRP) and the phosphorylation of ERK and AKT and therefore represents a novel strategy for treating bone cancer pain. The gene discussed is TFF2; the disease is bone cancer.